Korean Ministry of Culture

ROKIT HEALTHCARE Achieves European Certification for Cutting-Edge Organ Regeneration

Retrieved on: 
Lundi, août 14, 2023
DFU, EEA, Immigration (European Economic Area) Regulations 2006, 3D bioprinting, European Economic Community, Foot, MFDS, SNUH, Certification, Regenerative medicine, Transplant, Ulcer, Korean Ministry of Culture, Publication, Seoul National University Hospital, Artificial intelligence, European Medical Students' Association, Health, FDA, Kidney disease, Gangneung Asan Hospital, Medical device, EU, Food

SEOUL, South Korea, Aug. 14, 2023 /PRNewswire/ -- ROKIT HEALTHCARE, a pioneering biotech firm specializing in advanced organ regeneration, proudly announces a significant milestone.

Key Points: 
  • SEOUL, South Korea, Aug. 14, 2023 /PRNewswire/ -- ROKIT HEALTHCARE, a pioneering biotech firm specializing in advanced organ regeneration, proudly announces a significant milestone.
  • In July 2023, the company obtained the coveted certification under the European Medical Device Regulation (CEMDR) for its revolutionary "Dr. Invivo AI Regen Platform."
  • The "Dr. Invivo AI Regen Platform" marks a leap in organ regeneration and medical device innovation, fusing artificial intelligence (AI) with bioprinting.
  • SeokHwan You, CEO of ROKIT HEALTHCARE, states, "This certification propels us globally, extending advanced medical solutions."

Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Retrieved on: 
Mardi, août 8, 2023
PTN, Hypoactive sexual desire disorder, Fosun Pharma, Marketing, FTZ, MFDS, Woman, Prescription, Sale, Korean Ministry of Culture, Arousal, South Korea, Patient, HSDD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, NMPA, Safety, Medical tourism, Pharmaceutical industry, Bremelanotide, Palatine, Fosun International

Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in premenopausal women with HSDD.

Key Points: 
  • Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in premenopausal women with HSDD.
  • Data from this trial is anticipated by year end with a potential regulatory submission in the first half of 2024.
  • "This first commercial sale, coupled with the completed enrollment in the Phase 3 clinical trial in South Korea, strengthens our position in the Asian marketplace.
  • In exchange, Palatin received an upfront payment of $500,000 and is due a $3.0 million milestone based on the first commercial sale in Korea.

Almonty Partners with Korea Telecom to Revolutionize Mine Safety While Also Demonstrating Commitment to ESG Compliance

Retrieved on: 
Mardi, juillet 11, 2023
Technology, Mobile, Wireless, Other Technology, Telecommunications, Professional Services, Mining, Minerals, Hardware, Environmental, Social and Governance (ESG), Natural Resources, Bluetooth Low Energy, Communication, Partnership, AKTC, KT, Counties of South Sudan, KTC, AII, Korean Ministry of Culture, KT Corporation, Data analysis, Mine safety, Operating Industries Inc., Landfill, TSX, ESG, AI, Environment, Rest, Safety, Sangdong mine, Rare-earth element, Risk management, Mobile phone, Almonty Industries

Developed in partnership with KT, this innovative solution aims to enhance worker safety and promote efficient mining practices which is indicative of AKTC’s strong commitment to environmental, social, and governance (ESG) compliance.

Key Points: 
  • Developed in partnership with KT, this innovative solution aims to enhance worker safety and promote efficient mining practices which is indicative of AKTC’s strong commitment to environmental, social, and governance (ESG) compliance.
  • This AI-based mine safety system enables real-time monitoring of worker safety, emergency messaging, and data analysis allowing mine operators to take proactive safety measures.
  • In addition to improving safety standards, the Mine Safety DX technology also contributes to the efficient functioning of mining operations.
  • The implementation of Mine Safety DX at the Sangdong Mine further solidifies AKTC’s commitment to responsible and sustainable mining practices.

Deep Bio Secures Spot in South Korean Government's Prestigious "Super Gap Startup 1000+" Program

Retrieved on: 
Vendredi, juillet 7, 2023
Plaque, Neoplasm, MSS, Marie Cassidy, Intelligence, Stanford University School of Medicine, Research, Harvard University, Korean Ministry of Culture, Cancer, Patient, Skin, Growth, AI, SME, Biopsy, Prostate cancer, Medical device, Medical imaging

SEOUL, Korea, July 7, 2023 /PRNewswire-PRWeb/ -- Deep Bio Inc., a leader in artificial intelligence (AI)-powered cancer diagnostics, has been selected for the South Korean government's "Super Gap Startup 1000+" program. As a result of this selection, Deep Bio will receive up to 600 million KRW in funding over the next three years to drive its commercialization efforts.

Key Points: 
  • SEOUL, Korea, July 7, 2023 /PRNewswire-PRWeb/ -- Deep Bio Inc., a leader in artificial intelligence (AI)-powered cancer diagnostics, has been selected for the South Korean government's "Super Gap Startup 1000+" program.
  • The "Super Gap Startup 1000+" program is a national initiative aimed to foster high-tech startups that demonstrate unparalleled technological capabilities across 10 key industries.
  • "We are honored to be selected for the Super Gap Startup 1000+" program," said Sun Woo Kim, the CEO and Founder of Deep Bio.
  • Deep Bio's groundbreaking clinical research results have been published in prestigious medical journals, such as Cancers and npj Digital Medicine.

Joby Welcomes $100 Million Investment as It Expands Partnership With SK Telecom

Retrieved on: 
Jeudi, juin 29, 2023
Engineering, Other Manufacturing, Aerospace, Manufacturing, SK Telecom, JoeBen Bevirt, Partnership, Telecommunications, Aviation, Transport, SKM, Multimedia, TMAP, Joby Aviation, Government, Korean Ministry of Culture, SKT, Challenge, News, NYSE, Airline, Joby

Joby Aviation, Inc. (NYSE:JOBY), a company developing all-electric aircraft for commercial passenger service, today announced that SK Telecom (NYSE:SKM, “SKT”), South Korea’s leading telecommunications company, is making an equity investment of $100 million in Joby, as part of an expanded partnership between the two companies.

Key Points: 
  • Joby Aviation, Inc. (NYSE:JOBY), a company developing all-electric aircraft for commercial passenger service, today announced that SK Telecom (NYSE:SKM, “SKT”), South Korea’s leading telecommunications company, is making an equity investment of $100 million in Joby, as part of an expanded partnership between the two companies.
  • View the full release here: https://www.businesswire.com/news/home/20230629341584/en/
    The Joby aircraft flying in the skies over Marina, California.
  • Today’s investment is expected to lead to the development of further partnerships across the mobility ecosystem in Korea, led by SKT.
  • “We will do our utmost to promote the demonstration and commercialization of urban air mobility in Korea, based on our partnership with Joby Aviation,” added Ryu Young-sang, CEO of SKT.

Korea Pavilion at US AUTOMATE 2023 Garners Significant Response

Retrieved on: 
Vendredi, juin 16, 2023
Berry Good, Les Irois, AP, Automation, Badminton Korea Association, Robotics, KAR, UR, Advertising, Electronics, Attention, General Motors, Universal Robots, PLC, Exhibition, COVID-19, European Technology Platform on Smart Systems Integration, Windsor, Amazon, Korean Ministry of Culture, Disinfectant, SME, MGM, Twinnie-Lee Moore, Ford, NDA, Needle, Engine, COM, Indy, RS, Cobot, Mobile phone, Servo

SEOUL, June 16, 2023 /PRNewswire/ -- AUTOMATE 2023, renowned as the largest automation trade show in North America, was held from May 22nd to 25th in Detroit, Michigan.

Key Points: 
  • SEOUL, June 16, 2023 /PRNewswire/ -- AUTOMATE 2023, renowned as the largest automation trade show in North America, was held from May 22nd to 25th in Detroit, Michigan.
  • Korea Pavilion organized by Korea Association of Robot Industry(KAR) participated in this show, and received an overwhelmingly positive response; 9 companies in Korea Pavilion made their successful debuts at the show by presenting their flagship products and cutting-edge technologies.
  • In addition to this, we have already accomplished one of our main goals of participating in AUTOMATE 2023 : to enter Mexican market.
  • The official viewed Korean companies' participation in AUTOMATE 2023 as a significant milestone towards successful entry into the North American market.

Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

Retrieved on: 
Mercredi, juin 14, 2023
KRAS, CE, AACR, Takeda, Severance Hospital, ESR1, NGS, RT-PCR, Cancer, Business, BRAF, Janssen, Mutation, Research, PIK3CA, Certification, Strategy, MRD, Plasma, Korean Ministry of Culture, Bio-Rad Laboratories, Hospital, Acquisition, Patient, European, EGFR, Colorectal cancer, IVD, Samsung Medical Center, Amivantamab, POLE, Recurrence, PCR, Mobocertinib, Medical device, NSCLC, Food

SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.

Key Points: 
  • SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.
  • This product is a companion diagnostic test designed to detect EGFR mutations commonly found in NSCLC patients and guide the selection of appropriate targeted anticancer therapies based on the test results.
  • Compared to existing EGFR mutation tests using RT-PCR, this product demonstrates significantly higher sensitivity.
  • This is the second EGFR mutation test for which Gencurix has obtained approval.

ImmunoForge Expands Drug Development Licensing Agreement with Duke University

Retrieved on: 
Jeudi, mai 18, 2023
Duke University, IBM, US Food Sovereignty Alliance, Partnership, Commercialization, Polymyositis, Drug development, Therapy, DM, IIM, ODD, University, Clinical trial, Quality of life, Dermatomyositis, Research, Inflammation, ELP, Korean Ministry of Culture, Translation, US, Front vowel, Patient, Steroid, Myositis, FDA, Pharmaceutical industry, Food

Through this agreement, ImmunoForge expects to accelerate the development of new drugs based on the ELP technology that was originally developed by Professor Ashutosh Chilkoti at Duke University.

Key Points: 
  • Through this agreement, ImmunoForge expects to accelerate the development of new drugs based on the ELP technology that was originally developed by Professor Ashutosh Chilkoti at Duke University.
  • Dr. Jim Ballance, Chief Technology Officer (CTO) of ImmunoForge, has pioneered the clinical development of peptide drugs that are genetically fused to ELPs.
  • The powerful research partnership between ImmunoForge and Duke University will revolutionize the delivery of peptide and protein drugs.
  • "We are pleased to expand our relationship with ImmunoForge to continue development of novel therapeutics using the ELP platform, originally developed by Professor Chilkoti at Duke University", said Duke University Associate VP for Translation & Commercialization, Robin Rasor.

Consilient Inc. and Harex InfoTech Partner to Fight Financial Crime in South Korea

Retrieved on: 
Lundi, mai 8, 2023
Learning, Semiconductor, Partnership, Small modular reactor, Information, Terrorism, Privacy, Organization, Consilient, Korean Ministry of Culture, AML, MOU, Artificial intelligence, SMR, Quantum, SME, Cryptocurrency, AI

WASHINGTON, May 8, 2023 /PRNewswire/ -- Consilient, a fintech innovator aiming to transform financial crime compliance, announced it has partnered with Harex InfoTech, Inc. to transform the fight against financial crime in South Korea. The current technologies and methods for protecting the financial system are outdated, inefficient and largely ineffective. Through the use of federated learning (FL), a revolutionary form of artificial intelligence (AI), Consilient and Harex InfoTech will transform business processes and enable dynamic risk management to prevent financial crime in the South Korean market.

Key Points: 
  • WASHINGTON, May 8, 2023 /PRNewswire/ -- Consilient , a fintech innovator aiming to transform financial crime compliance, announced it has partnered with Harex InfoTech, Inc. to transform the fight against financial crime in South Korea.
  • Through the use of federated learning (FL), a revolutionary form of artificial intelligence (AI), Consilient and Harex InfoTech will transform business processes and enable dynamic risk management to prevent financial crime in the South Korean market.
  • The Consilient and Harex InfoTech partnership forms a US-Korean AI technology alliance that will enhance the effectiveness and efficiency of Korean financial institutions in combatting financial crime.
  • "Consilient was founded to change fundamentally how financial institutions and regulators worldwide prevent financial crime.

MEDICAL IP Is Creating Medical Digital Twins in Virtual Spaces, Powered by NVIDIA Omniverse

Retrieved on: 
Lundi, mai 8, 2023
CT, Mayo Clinic, Nvidia Omniverse, 3D, Multimedia, USD, Korean Ministry of Culture, MRI, US, Seoul National University Hospital, Patient, European, NVIDIA, Arizona State University, Inception, Artificial intelligence, Samsung Medical Center, UCLA, AR, Software, Medical imaging, Medical device, Video game, Omniverse, Food

Among all software around the world, MEDIP PRO is the first and only case to combine medical software based on medical image data with Omniverse.

Key Points: 
  • Among all software around the world, MEDIP PRO is the first and only case to combine medical software based on medical image data with Omniverse.
  • The Omniverse development platform is optimized for developing custom 3D pipelines and simulating virtual worlds, including digital twins.
  • "With Omniverse, users around the world can more easily leverage MEDIP PRO to expand medical digital twins into the metaverse, which will maximize the competitiveness of our products."
  • At present, MEDIP PRO is being supplied to university hospitals, medical schools, specialized medical high schools, medical device companies, and others.